Mykrox Side Effects
Generic name: metolazone
Note: This document contains side effect information about metolazone. Some of the dosage forms listed on this page may not apply to the brand name Mykrox.
Some side effects of Mykrox may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to metolazone: oral tablet
Get emergency medical help if you have any of these signs of an allergic reaction while taking metolazone (the active ingredient contained in Mykrox) hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using this medication and call your doctor at once if you have a serious side effect such as:
dry mouth, thirst, nausea, vomiting;
feeling weak, drowsy, restless, or light-headed;
fast or uneven heartbeat;
muscle pain or weakness;
urinating less than usual or not at all; or
numbness or tingly feeling.
Less serious side effects of metolazone may include:
a red, blistering, peeling skin rash; or
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For Healthcare Professionals
Applies to metolazone: oral tablet
A rare case of hyperosmolar nonketotic hyperglycemia is associated with metolazone (the active ingredient contained in Mykrox)
Metabolic side effects are the most common and profound. The rapid onset of hyponatremia or hypokalemia is often sudden and may be profound, particularly if metolazone is given with a loop diuretic. Hypokalemia may be important in patients with underlying cardiac arrhythmias. Metolazone may increase serum calcium and uric acid levels and lower serum magnesium and phosphate levels. Glucose intolerance is reported in rare cases.
Cardiovascular side effects are uncommon. Postural hypotension is reported in less than 5% of patients. Rare cases of venous thrombosis are reported, thought to be due to metolazone-induced hypovolemia and increased serum concentrations of clotting factors. Rare cardiovascular side effects also include palpitations, hypovolemia, and chest pain.
Renal insufficiency, manifest as a rise in serum creatinine and BUN, may occur, although, in most cases, creatinine clearance increases as a result of metolazone (the active ingredient contained in Mykrox) therapy.
Nervous system side effects include headache, dizziness, and fatigue. Two cases of syncope and seizures are reported. Metolazone-induced hypovolemia and electrolyte changes may induce hepatic encephalopathy in some patients.
It is not clear whether the patients who developed syncope and seizure activity were hypotensive or hypovolemic at the time of the seizures or that metolazone can definitively be implicated. In one case the patient was also taking theophylline and had hypomagnesemia, which may be a complication of metolazone therapy.
Hypersensitivity reactions include rare case reports of necrotizing vasculitis, angiitis, and pruritic rashes.
A case of cutaneous hypersensitivity angiitis has been reported in a patient who had previously tolerated thiazide diuretics, indicating that, despite the chemical similarity between thiazides and metolazone, there is not necessarily cross-reactivity.
Hematologic abnormalities are rare. Cases of reversible hypoplastic anemia, aplastic anemia, agranulocytosis, and mild leukopenia are reported.
Gastrointestinal side effects are rare, and include a case of acute pancreatitis. Nausea, vomiting, anorexia, and abdominal bloating are also rare.
Hepatic side effects include a rare case of cholestatic jaundice.
Musculoskeletal cramps are associated with metolazone (the active ingredient contained in Mykrox) therapy, as with other diuretics, and may be associated with electrolyte disorders and rapid intravascular volume shifts.
More Mykrox resources
- Mykrox Prescribing Information (FDA)
- Mykrox Advanced Consumer (Micromedex) - Includes Dosage Information
- Metolazone Prescribing Information (FDA)
- Metolazone Professional Patient Advice (Wolters Kluwer)
- metolazone Concise Consumer Information (Cerner Multum)
- metolazone MedFacts Consumer Leaflet (Wolters Kluwer)
- Metolazone Monograph (AHFS DI)
- Zaroxolyn Prescribing Information (FDA)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.